Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
The unstoppable duo of Emma Stone and Yorgos Lanthimos
Envision, Suez ink battery park partnership
Best of geology, topography, botany & anthropology
Voters demand crackdown on pro
Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
Fallacies and facts about China's 'overcapacity'
Biden says Brown v. Board of Education ruling was about more than education
Bayern without fans against Arsenal, Dortmund facing knockout monsters Atletico